COMpulsive Gambling: Efficacy of DEEP Transcranial Magnetic Stimulation With H7 COIL (COMET-7)
15 września 2026 zaktualizowane przez: Sveti Ivan Psychiatric Hospital
This study aims to investigate whether a treatment called high-frequency repetitive transcranial magnetic stimulation (rTMS) can help reduce the symptoms of gambling disorder and whether it is safe and well tolerated.
The study will include 60 men aged 18-64 years who have been diagnosed with gambling disorder and are starting treatment at the Gambling Disorder Day Hospital of UPC Sveti Ivan in Zagreb.
Participants will be randomly assigned to one of two groups. One group will receive active rTMS treatment using the H7 coil, while the other group will receive a sham (placebo) treatment that looks and feels similar but does not provide the active magnetic stimulation. Neither the participants nor the researchers assessing the results will know which treatment each participant received during the study. All participants will continue to receive their usual treatment.
The study will last six weeks. Participants will complete questionnaires before treatment and six weeks after the intervention. The main goal is to determine whether rTMS reduces the severity of gambling-related symptoms.
The researchers will also examine whether personal, psychological, and clinical characteristics can help predict who is most likely to benefit from rTMS. In addition, the study will investigate whether rTMS affects autonomic nervous system regulation, measured through heart rate variability (HRV), and will assess the economic impact of this treatment.
Overall, the study is intended to provide better information about the effectiveness, safety, possible predictors of treatment response, effects on the body's regulation, and cost-effectiveness of rTMS for gambling disorder.
Przegląd badań
Status
Jeszcze nie rekrutacja
Warunki
Interwencja / Leczenie
Typ studiów
Interwencyjne
Zapisy (Szacowany)
60
Faza
- Nie dotyczy
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
Akceptuje zdrowych ochotników
Nie
Opis
Inclusion Criteria:
- confirmed GD diagnosis according to ICD-10 (F63.0)
- age between 18 and 64 years
- male gender
- enrolled in GD treatment at the GD-DH of the UPC Sveti Ivan within two weeks of study inclusion.
- right-hand dominance
Exclusion Criteria:
- diagnosis of a schizophrenia spectrum disorder (ICD-10, F20-F29)
- diagnosed psychotic episode within six months prior to inclusion
- current suicidality
- clinically relevant neurological disorder or history of cerebrovascular insult
- diagnosis of a mental and behavioral disorder due to the use of psychoactive substances (ICD-10, F10-F19) (except nicotine dependence)
- diagnosed moderate or severe dementia
- presence of intracranial implants
- inability to independently complete questionnaires
- refusal to participate due to discomfort during DLPFC localization
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Poczwórny
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Aktywny komparator: 30 patients who will receive active r-TMS treatment
|
The intervention will involve rTMS treatment using the H7 coil (Brainsway Ltd., Jerusalem, Israel) with the following parameters: Magnetic field intensity: 100% of the observed motor threshold, frequency: 20 Hz, stimulation duration: 2 seconds, pause between stimulations: 20 seconds, number of stimulations: 50, number of magnetic pulses per session: 2,000, session duration: ≈18 minutes, total intervention duration: one session per day, five days per week, for five weeks, followed by one session per day for four days in the sixth week, total number of pulses: 58,000.
|
|
Pozorny komparator: 30 patients who will receive sham r-TMS treatment
|
The control group will receive sham rTMS using an H7 coil (Brainsway Ltd., Jerusalem, Israel), administered identically to active rTMS treatment.
The sham coil is positioned above the active coil within the device, ensuring that its shape, pulsing sound, and subjective sensation of stimulation are indistinguishable from the active rTMS coil, but without generating electromagnetic induction.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Gambling Symptom Assessment Scale (G-SAS)
Ramy czasowe: six weeks
|
The primary outcome will be the change in the severity of gambling disorder (GD), measured using the Gambling Symptom Assessment Scale (G-SAS), the most commonly used scale for assessing changes in GD symptom severity in research studies.
Each item on the G-SAS is rated on a 5-point scale, ranging from 0 (no symptoms) to 4 (extreme symptoms).
The total score can range from 0 to 48.
Higher scores indicate greater severity of gambling-related symptoms.
|
six weeks
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Gambling Urges Scale (GUS)
Ramy czasowe: six weeks
|
The Gambling Urge Scale (GUS) is a 6-item questionnaire designed to measure an individual's current urge or craving to gamble, on a 7-point scale.
Responses are summed for a total score; higher scores reflect stronger immediate cravings or urges to gamble.
|
six weeks
|
|
Visual Analog Scale (VAS)
Ramy czasowe: six weeks
|
The Visual Analog Scale (VAS) is a continuous measurement instrument used to quantify subjective internal experiences of pain.
It consists of a line with word descriptors placed at opposite extremes ("No pain" at 0 mm and "Worst pain imaginable" at 100 mm).
|
six weeks
|
|
drop-outs
Ramy czasowe: six weeks
|
the number of participants who discontinued treatment
|
six weeks
|
|
Yale-Brown Obsessive Compulsive Scale adapted for GD (PG-YBOCS)
Ramy czasowe: six weeks
|
Reduction in the severity of obsessive-compulsive symptoms related to GD, measured using the Yale-Brown Obsessive Compulsive Scale adapted for GD (PG-YBOCS).
The scale evaluates the intensity, frequency, and impact of gambling urges, thoughts, and behaviors.
It features 10 items scored from 0 to 4, yielding a total score from 0 to 40.
|
six weeks
|
|
South Oaks Gambling Screen (SOGS)
Ramy czasowe: six weeks
|
Reduction in GD severity, assessed through changes in total scores on the South Oaks Gambling Screen (SOGS), the most widely used instrument for evaluating GD severity.
It is a 20-item questionnaire used to screen for problem gambling and pathological gambling behaviors.
It contains multiple informational questions, and each "at-risk" answer earns 1 point.
|
six weeks
|
|
Problem Gambling Severity Index (PGSI)
Ramy czasowe: six weeks
|
Problem Gambling Severity Index (PGSI) is a widely recognized, standardized 9-item self-report questionnaire used to assess the severity of gambling behaviors and their negative consequences.
Each question is scored on a 4-point scale (0 = Never; 1 = Sometimes; 2 = Often; 3 = Almost always / Always), yielding a total score from 0 to 27.
|
six weeks
|
|
gambling abstinence
Ramy czasowe: six weeks
|
gambling abstinence, assessed daily throughout the intervention period
|
six weeks
|
|
Beck Depression Inventory-II (BDI-II)
Ramy czasowe: six weeks
|
Reduction in depressive symptoms, measured using the Beck Depression Inventory-II (BDI-II).
It is a widely used 21-item self-report questionnaire designed to measure the severity of depressive symptoms.
Each item is scored on a 4-point Likert scale ranging from 0 to 3, where higher numbers reflect greater symptom intensity.
|
six weeks
|
|
Beck Anxiety Inventory (BAI)
Ramy czasowe: six weeks
|
Reduction in anxiety symptoms, assessed using the Beck Anxiety Inventory (BAI).
It is a 21-item self-report questionnaire used to measure the severity of an adult or adolescent's anxiety symptoms over the past week.
It contains questions rated on a 4-point scale from 0 to 3, and greater scores means greater anxiety.
|
six weeks
|
|
Quality of Life Inventory (QOLI)
Ramy czasowe: six weeks
|
Improvement in quality of life, measured using the Quality of Life Inventory (QOLI), the most frequently used tool for assessing quality-of-life.
It measures an individual's happiness and life satisfaction across 16 key areas.
It consists of 32 items measuring both the importance of each domain (on a 3-point scale) and current satisfaction with it (on a 6-point scale).
|
six weeks
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
Ramy czasowe: six weeks
|
The incidence of adverse events, including headache, neck pain, scalp discomfort, tingling, burning sensations, skin redness, drowsiness, sleep disturbances, back pain, difficulty concentrating, acute mood changes, hearing impairment, facial muscle spasms or twitches, dizziness, nausea, lightheadedness, or any other adverse event (self-reported and recorded by clinicians)
|
six weeks
|
|
Discontinuation of the treatment due to adverse events
Ramy czasowe: six weeks
|
The proportion of patients whose intervention was discontinued due to adverse events
|
six weeks
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Sponsor
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
1 października 2026
Zakończenie podstawowe (Szacowany)
1 kwietnia 2027
Ukończenie studiów (Szacowany)
1 grudnia 2027
Daty rejestracji na studia
Pierwszy przesłany
7 września 2026
Pierwszy przesłany, który spełnia kryteria kontroli jakości
15 września 2026
Pierwszy wysłany (Rzeczywisty)
18 września 2026
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
18 września 2026
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
15 września 2026
Ostatnia weryfikacja
1 września 2026
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- IP-2025-02
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Nie
Bada produkt urządzenia regulowany przez amerykańską FDA
Nie
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .